Nasus Pharma to Present at H.C. Wainwright Conference Amid NS002 Development Push
Event summary
- Nasus Pharma to present at H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026 in New York.
- CEO Brendan O’Grady and CFO Eyal Rubin will hold one-on-one investor meetings during the event.
- Company’s lead product candidate NS002 is an intranasal epinephrine treatment for Type I allergic reactions.
- Nasus Pharma aims to advance NS002 toward a pivotal trial in Q4 2026 with topline data readout in Q1 2027.
The big picture
Nasus Pharma’s participation in the H.C. Wainwright conference comes as it prepares for a critical phase in NS002’s development, aiming to address a significant unmet medical need in anaphylaxis treatment. The company’s focus on intranasal drug delivery aligns with broader industry trends toward patient-friendly, rapid-acting therapies. Success in this space could position Nasus Pharma as a key player in the competitive allergy and anaphylaxis treatment market.
What we're watching
- Clinical Milestones
- The pace at which NS002 advances toward pivotal trial and data readout will signal development progress.
- Investor Sentiment
- How investor meetings at the conference impact Nasus Pharma’s valuation and market perception.
- Commercial Strategy
- Whether Nasus Pharma can effectively communicate its pre-commercial planning and pipeline potential.